A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus (NCT07662109)
A Randomized, Double-blind, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron and Dapagliflozin in Combination, Compared With Elecoglipron Alone and Dapagliflozin Alone, in Adults With Type 2 Diabetes Mellitus (Eluminate-5)
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to evaluate the efficacy, safety, and tolerability of elecoglipron and dapagliflozin in combination, compared with elecoglipron alone and dapagliflozin alone, in adults with type 2 diabetes mellitus (T2DM) inadequately managed with lifestyle management alone or treated with other background glucose-lowering medication.
Who can join: Review the eligibility criteria below.
Location: Research Site — Huntsville, Alabama
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (282 Sites)
Showing the first 25 of 282 sites.
- Research Site — Huntsville, Alabama
- Research Site — Mobile, Alabama
- Research Site — Sheffield, Alabama
- Research Site — Little Rock, Arkansas
- Research Site — Bakersfield, California
- Research Site — Los Angeles, California
- Research Site — Ontario, California
- Research Site — Lake City, Florida
- Research Site — Lakeland, Florida
- Research Site — Atlanta, Georgia
- Research Site — Chicago, Illinois
- Research Site — Skokie, Illinois
- Research Site — Evansville, Indiana
- Research Site — Sioux City, Iowa
- Research Site — Zachary, Louisiana
- Research Site — Annapolis, Maryland
- Research Site — Lutherville-Timonium, Maryland
- Research Site — Oxon Hill, Maryland
- Research Site — Boston, Massachusetts
- Research Site — Boston, Massachusetts
- Research Site — Troy, Michigan
- Research Site — Ridgeland, Mississippi
- Research Site — Elkhorn, Nebraska
- Research Site — Albuquerque, New Mexico
- Research Site — Brooklyn, New York
📞 Contact the Study Coordinator
Phone: (877) 240-9479
Email: information.center@astrazeneca.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Type 2 Diabetes Mellitus
- Renal HEIR Study: Renal Hemodynamics, Energetics and Insulin Resistance in Youth Onset Type 2 Diabetes Study — Aurora, Colorado
- A Study to Compare Different Doses of RO7795081 With a Placebo or Semaglutide in People With Type 2 Diabetes — Tucson, Arizona
- Preventing Type 2 Diabetes in Black Emergent Adult — Chapel Hill, North Carolina
- Safety and Effectiveness of Endoscopic Intestinal Re-Cellularization Therapy in Individuals With Type II Diabetes — Birmingham, Alabama
- Proact: A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease — Huntsville, Alabama
- GLP-1 and Hypoglycemia — Baltimore, Maryland
Explore by condition: All Type 2 Diabetes Mellitus clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.